GEMINA LABORATORIES LTD. Financials Gemina Laboratories Ltd.
Equities
GLAB
CA3686501071
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.47 CAD | +4.44% |
|
-9.62% | -12.96% |
| 04-02 | Gemina Laboratories Sign First Strategic License Agreement | CI |
| 03-18 | Gemina Laboratories Ltd. announced that it has received CAD 0.91 million in funding | CI |
Valuation
| Fiscal Period: January | 2022 | 2023 |
|---|---|---|
| Capitalization 1 | 27.47 | 44.87 |
| Enterprise Value (EV) 1 | 26.36 | 45.03 |
| P/E ratio | -5.03 x | -7.05 x |
| Yield | - | - |
| Capitalization / Revenue | - | - |
| EV / Revenue | - | - |
| EV / EBITDA | -5,583,864 x | -7,548,311 x |
| EV / FCF | -9,687,634 x | -19,122,384 x |
| FCF Yield | -0% | -0% |
| Price to Book | 29.4 x | -642 x |
| Nbr of stocks (in thousands) | 54,936 | 64,099 |
| Reference price 2 | 0.5000 | 0.7000 |
| Announcement Date | 31/05/22 | 31/05/23 |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: January | 2021 | 2022 | 2023 |
|---|---|---|---|
| Net sales | - | - | - |
| EBITDA | - | -4.72 | -5.965 |
| EBIT 1 | -0.6697 | -4.734 | -5.98 |
| Operating Margin | - | - | - |
| Earnings before Tax (EBT) 1 | -1.112 | -4.735 | -5.979 |
| Net income 1 | -1.112 | -4.735 | -5.979 |
| Net margin | - | - | - |
| EPS 2 | -0.0330 | -0.0994 | -0.0993 |
| Free Cash Flow | - | -2.721 | -2.355 |
| FCF margin | - | - | - |
| FCF Conversion (EBITDA) | - | - | - |
| FCF Conversion (Net income) | - | - | - |
| Dividend per Share | - | - | - |
| Announcement Date | 28/07/21 | 31/05/22 | 31/05/23 |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: January | 2021 | 2022 | 2023 |
|---|---|---|---|
| Net Debt 1 | - | - | 0.16 |
| Net Cash position 1 | 0.78 | 1.11 | - |
| Leverage (Debt/EBITDA) | - | - | -0.0264 x |
| Free Cash Flow | - | -2.72 | -2.35 |
| ROE (net income / shareholders' equity) | - | -858% | -1,371% |
| ROA (Net income/ Total Assets) | - | -150% | -227% |
| Assets 1 | - | 3.158 | 2.636 |
| Book Value Per Share 2 | 0 | 0.0200 | -0 |
| Cash Flow per Share 2 | 0.0200 | 0.0200 | 0 |
| Capex | - | 0.01 | 0.08 |
| Capex / Sales | - | - | - |
| Announcement Date | 28/07/21 | 31/05/22 | 31/05/23 |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -12.96% | 25.48M | |
| -4.67% | 12.32B | |
| -5.19% | 8.07B | |
| +9.45% | 5.91B | |
| +28.50% | 5.52B | |
| -8.09% | 4.21B | |
| +13.49% | 2.73B | |
| -1.34% | 2.43B | |
| +32.24% | 2.29B | |
| -3.55% | 1.89B |
- Stock Market
- Equities
- GLAB Stock
- Financials Gemina Laboratories Ltd.
